US3574137A - Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium - Google Patents

Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium Download PDF

Info

Publication number
US3574137A
US3574137A US802263A US3574137DA US3574137A US 3574137 A US3574137 A US 3574137A US 802263 A US802263 A US 802263A US 3574137D A US3574137D A US 3574137DA US 3574137 A US3574137 A US 3574137A
Authority
US
United States
Prior art keywords
blood cells
red blood
human
cells
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US802263A
Inventor
Anthony J Decasperis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of US3574137A publication Critical patent/US3574137A/en
Assigned to WARNER-LAMBERT COMPANY, A CORP. OF DE. reassignment WARNER-LAMBERT COMPANY, A CORP. OF DE. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: PFIZER INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Definitions

  • This invention relates to a diagnostic hematology composition. More particularly, it relates to a stabilized and standardized suspension of blood cells that provides a reference control for a number of routine hematologic determinations.
  • the distinguishing feature of this invention resides in the preparation of a stable multiple-analysis reference control which combines in a single composition reference controls for red blood cell and white blood counting, hemoglobin content, hematocrit determination, and allows by mathematical computation, the calculation of mean corpuscular volume and mean corpuscular hemoglobin concentration, and mean corpuscular hemoglobin.
  • An embodiment of this invention is the preparation of a stable cell suspension that approximates the composition of normal human blood. Oxalated or citrated whole human blood has limited stability on storage. Red blood cells slowly hemolyze and undergo changes in size and shape. Similarly, white blood cells suffer degenerative changes.
  • a novel feature of this invention is the preparation of a stable red blood cell suspension that serves as a reference control for human white blood cells.
  • Human white blood cells are not suitable for control purposes, especially in the presence of red blood cells, because they are unstable, excreting a lysozyme type of enzyme that attacks red blood cells.
  • Avian red blood cells are larger than human red blood cells, and approximate the size and shape of human white blood cells.
  • fowl red blood cells such as goose, chicken, duck, and preferably turkey red blood cells, close- 1y match the size and shape of human white blood cells, and lend themselves nicely to the subject tanning process.
  • These stabilized simulated white blood cells provide a satisfactory substitute for human white blood cells in our composition control product.
  • Suspensions of human red blood cells and simulated white blood cells are mixed in such proportion that the final red blood cell and white blood cell counts, hemoglobin content and hematocrit fall in the range considered normal for human blood.
  • the normal range in human blood for red blood cells is 4,000,000-5,000,000 cells/mm. and for white blood cells the count is 5,000l0,000 cells/mmfi.
  • the normal hemoglobin value is l2-16 grams/ ml.
  • the term hematocrit is defined as the ratio of volume of packed red blood cells to the volume of whole blood. The normal ratio in humans is about 45%.
  • the means corpuscular volume is the ratio of the volume of packed red cells in ml. per liter of blood to red blood cells in millions per cubic millimeter.
  • the mean corpuscular hemoglobin concentration is an index indicating the mean or average weight of hemoglobin per 100 ml. of packed red blood cell in terms of percent.
  • the mean corpuscular hemoglobin is the ratio of hemoglobin content in grams per liter to red blood cells in millions per cubic millimeter.
  • control product must accurately indicate on a comparative basis what a test sample of blood constitutes with regard to the above determinations. It is further evident how important it is for the control product to simulate non-treated cells. It follows, for instance, that if the control product contains cells that differ materially in size, the experimental results will be inaccurate, if not wholly meaningless. In essence, the cells treated by the method disclosed herein provides an excellent system of checks and balances so necessary in hematologic determinations.
  • this invention embodies a composition prepared by mixing a suspension of human red blood cells with a suspension of stabilized fowl red blood cells (simulated human white blood cells) in such proportions as to provide in a single composition a multiple-analysis reference control for red blood cell and white blood cell counting, hemoglobin content and hematocrit determination.
  • saline throughout can be any of the following three solutions: 0.9% by weight aqueous sodium chloride solution which is designated by the term solution A; 0.45% by weight aqueous sodium chloride solution designated as solution B; or a buffered saline solution (solution C).
  • solution A 0.9% by weight aqueous sodium chloride solution
  • solution B 0.45% by weight aqueous sodium chloride solution
  • solution C a buffered saline solution
  • the first step of the herein disclosed method for stabilizing fowl red blood cells consists of suspending the red cells in saline to provide up to a 50% volume suspension. Although a concentration as high as 50% will work, it is preferred to use a range from about 5% to about 10% by volume, and even more preferred to use an 8% suspension. This suspension is combined with an equal volume of a 1 to 3% solution by weight of mercuric chloride in saline.
  • the second step consists of heating the resulting mixture at 37 C. for at least 12 hours, and preferably for about 19-20 hours.
  • the solid materials are recovered by centrifugation and separation, and then resuspended in saline, as a 2-6%, and preferably a 4% suspension.
  • the third step consists of combining with the aforesaid suspension, an equal volume of a 0.0025% w./v. solution of aqueous tannic acid in saline with thorough mixing,
  • the saline solution containing the tannic acid is a buffered saline solution having a pH of 7.2, and is the solution C referred to earlier. Its preparation consists of the following reagents in the proportions indicated (per liter).
  • red blood cells from any blood type can be used.
  • Group blood cells are preferably used because of the ready availability of blood donors of this type. Pooled Group 0 blood, collected in acid citrate-dextrose anticoagulant solution, is centrifuged, and the supernatant removed and set aside, and the buffy layer of white blood cells gently removed and discarded. The packed red blood cells are washed several times with Alsevers solution, reconstituted in Alsevers solution, and stored at 2-8 C.
  • the resuspending medium used for the final suspension of the human red blood cells, is prepared from defibrinated plasma that is serologically compatible with the suspended human red blood cells, i.e., Group A cells with plasma from Group A, Group B cells with plasma from Group B and Group 0 cells with plasma from Group 0.
  • Defibrinated Group AB plasma (lacking antigens A and B) is compatible with Group A, Group B and Group 0 red blood cells.
  • These plasma supernatants are defibrinated by treatment with bovine thrombin and then diluted 1:3 with Alsevers solution.
  • a metabolic preservative selected from the class of compounds comprising purines and pyrimidines, is added to the suspending medium at a final concentration of about 34-35 mg. per 100 ml. of cell suspension.
  • a particularly effective preservative agent is adenine (6-arninopurine or a pharmaceutically acceptable acid addition salt, Mann Research Laboratories, Inc., New York, N.Y.).
  • EXAMPLE I Group 0 blood, collected in aqueous acid citratedextrose anticoagulant, is centrifuged under sterile conditions at 2000 r.p.m. for 20 minutes. The supernatant is gently suctioned off, care being taken not to draw into the supernatant any of the red cells or bufly white layer at the interface of the red cells and supernatant. The supernatant is retained for subsequent dilution with Alsevers solution, and used as a resuspending medium.
  • the bufly layer (white blood cells) is carefully removed from the top of the packed red blood cells, withdrawing a thin surface of red cells if necessary.
  • the packed red cells are washed twice with Alsevers solution, centrifuged, and stored at 2-8 C. until subsequent mixture With stabilized simulated white blood cells.
  • Fowl red blood cells preferably turkey cells
  • saline solution A
  • saline solution A
  • saline solution A
  • mercuric chloride a 1% solution by weight of mercuric chloride in saline
  • solution A a 4% 4 by volume suspension.
  • solution C a 0.0025% weight/volume solution of tannic acid in buffered saline
  • EXAMPLE III The supernatant plasma, obtained from Group 0 bloods collected in aqueous acid citrate-dextrose anticoagulant, is diluted with 1:3 with Alsevers solution.
  • the diluted plasma is defibrinated by adding bovine thrombin (Parke- Davis & Co., Detroit, Michigan) at a concentration of 1 unit/ml, and incubated at 37 C. for 1 hour.
  • bovine thrombin Parke- Davis & Co., Detroit, Michigan
  • the clotted material is shaken vigorously to break up the clot, and filtered through a No. 50 Whatman filter pad on a Buchner funnel-suction flask set-up.
  • Adenine sulfate is added at a concentration of 70' mgs./ 100 ml., warming at 37 C. to hasten the dissolution, and the solution filtered successively through 0.45 and 0.22 millipore filter pads.
  • EXAMPLE IV The method of Example III with plasma from Group AB blood in place of Group 0 plasma.
  • EXAMPLE V The simulated white blood cells prepared by the method of Example II are reconstituted in sterile A1- severs solution to about 24% hematocrit. This has an approximate count of 750,000-800,000 cells/mmfi. Two m1. of this suspension is further diluted by the addition of 100 ml. of the resuspending medium as prepared by the method of Example III or Example IV.
  • the final cell suspension product containing approximately 34-35 mg./ ml. of adenine, has a red blood cell count of about 4,000,000-5,000,000 cells/mmfi, white blood cell count of 5,000-10,000 cells/mm hemoglobin, 12-16 grams/100 ml., and hematocrit, 43-47%.
  • a hematology control fluid comprising a suspension of fresh human red blood cells and tanned fowl red blood cells in a volume of anticoagulant-containing human serologically compatible plasma medium, approximately equal to the packed volume of said human cells at a concentration of about 5,000-l0,000 of said fowl cells per cubic millimeter.
  • said plasma medium comprises defibrinated human plasma in aqueous acid citrate-dextrose anticoagulant diluted with Alsevers solution in a volume ratio of about 1:3.

Abstract

A DIAGNOSTIC COMPOSITION SERVING AS A MULTIPLE-ANALYSIS HEMATOLOGY REFERENCE CONTROL FOR RED BLOOD CELL AND WHITE BLOOD CELL COUNTING, HEMOGLOBIN CONTENT AND HEMATOCRIT DETERMINATION.

Description

United States Patent 3,574,137 MULTIPLE-ANALYSIS HEMATOLOGY CONTROL COMPRISING HUMAN RED BLOOD CELLS AND FOWL RED BLOOD CELLS IN AN ANTICOAGU- LANT CONTAINING HUMAN SEROLOGICALLY COMPATIBLE PLASMA MEDIUM Anthony J. Decasperis, Elmhurst, N.Y., assignor to Pfizer Inc., New York, N.Y. N0 Drawing. Filed Feb. 25, 1969, Ser. No. 802,263 Int. Cl. G01n 33/16 US. Cl. 252-408 9 Claims ABSTRACT on THE DISCLOSURE A diagnostic composition serving as a multiple-analysis hematology reference control for red blood cell and white blood cell counting, hemoglobin content and hematocrit determination.
BACKGROUND OF THE INVENTION This invention relates to a diagnostic hematology composition. More particularly, it relates to a stabilized and standardized suspension of blood cells that provides a reference control for a number of routine hematologic determinations.
Up to now, the prior art of hematology determinations has suffered from the lack of stable reference controls. With the advent of automated devices capable of performing multiple hematological determinations, a growing need has developed for cross-reference samples for manual and automated machine analyses.
The distinguishing feature of this invention resides in the preparation of a stable multiple-analysis reference control which combines in a single composition reference controls for red blood cell and white blood counting, hemoglobin content, hematocrit determination, and allows by mathematical computation, the calculation of mean corpuscular volume and mean corpuscular hemoglobin concentration, and mean corpuscular hemoglobin.
An embodiment of this invention is the preparation of a stable cell suspension that approximates the composition of normal human blood. Oxalated or citrated whole human blood has limited stability on storage. Red blood cells slowly hemolyze and undergo changes in size and shape. Similarly, white blood cells suffer degenerative changes.
A novel feature of this invention is the preparation of a stable red blood cell suspension that serves as a reference control for human white blood cells. Human white blood cells are not suitable for control purposes, especially in the presence of red blood cells, because they are unstable, excreting a lysozyme type of enzyme that attacks red blood cells. Avian red blood cells are larger than human red blood cells, and approximate the size and shape of human white blood cells. For purposes of this invention it has been found that fowl red blood cells such as goose, chicken, duck, and preferably turkey red blood cells, close- 1y match the size and shape of human white blood cells, and lend themselves nicely to the subject tanning process. These stabilized simulated white blood cells provide a satisfactory substitute for human white blood cells in our composition control product.
It has been found that fresh human red blood cells, stabilized by suspension in human plasma or serum with added metabolic preservative, satisfactorily provide the red blood cells component of the subject composition. Plasma or serum provide some of the necessary electrolytes and proteins necessary for red blood metabolic stability. Selected purines or pyrimidines act as additional metabolic preservatives. The untauned red blood cells are readily hemolyzed in the prior operational step for the white blood cell count and subsequent hemoglobin determination.
Suspensions of human red blood cells and simulated white blood cells are mixed in such proportion that the final red blood cell and white blood cell counts, hemoglobin content and hematocrit fall in the range considered normal for human blood.
The normal range in human blood for red blood cells is 4,000,000-5,000,000 cells/mm. and for white blood cells the count is 5,000l0,000 cells/mmfi. The normal hemoglobin value is l2-16 grams/ ml. The term hematocrit is defined as the ratio of volume of packed red blood cells to the volume of whole blood. The normal ratio in humans is about 45%. The means corpuscular volume is the ratio of the volume of packed red cells in ml. per liter of blood to red blood cells in millions per cubic millimeter. The mean corpuscular hemoglobin concentration is an index indicating the mean or average weight of hemoglobin per 100 ml. of packed red blood cell in terms of percent. The mean corpuscular hemoglobin is the ratio of hemoglobin content in grams per liter to red blood cells in millions per cubic millimeter.
It is evident that a control product must accurately indicate on a comparative basis what a test sample of blood constitutes with regard to the above determinations. It is further evident how important it is for the control product to simulate non-treated cells. It follows, for instance, that if the control product contains cells that differ materially in size, the experimental results will be inaccurate, if not wholly meaningless. In essence, the cells treated by the method disclosed herein provides an excellent system of checks and balances so necessary in hematologic determinations.
SUMMARY OF THE INVENTION In general, this invention embodies a composition prepared by mixing a suspension of human red blood cells with a suspension of stabilized fowl red blood cells (simulated human white blood cells) in such proportions as to provide in a single composition a multiple-analysis reference control for red blood cell and white blood cell counting, hemoglobin content and hematocrit determination.
DETAILED DESCRIPTION OF THE INVENTION Regarding the novel methods to be described, it is to be understood that the term saline throughout can be any of the following three solutions: 0.9% by weight aqueous sodium chloride solution which is designated by the term solution A; 0.45% by weight aqueous sodium chloride solution designated as solution B; or a buffered saline solution (solution C). In the preparation of the simulated white blood cell control, it is important to use the 0.45% solution (solution B) for the reason that this concentration advantageously tends to modify the normal shape of fowl red blood cells which are oval to a more circular shape like human white blood cells.
The first step of the herein disclosed method for stabilizing fowl red blood cells consists of suspending the red cells in saline to provide up to a 50% volume suspension. Although a concentration as high as 50% will work, it is preferred to use a range from about 5% to about 10% by volume, and even more preferred to use an 8% suspension. This suspension is combined with an equal volume of a 1 to 3% solution by weight of mercuric chloride in saline.
The second step consists of heating the resulting mixture at 37 C. for at least 12 hours, and preferably for about 19-20 hours. The solid materials are recovered by centrifugation and separation, and then resuspended in saline, as a 2-6%, and preferably a 4% suspension.
The third step consists of combining with the aforesaid suspension, an equal volume of a 0.0025% w./v. solution of aqueous tannic acid in saline with thorough mixing,
3 incubating the resulting mixture, and recovering the solid mixture by centrifugation and separation. The saline solution containing the tannic acid is a buffered saline solution having a pH of 7.2, and is the solution C referred to earlier. Its preparation consists of the following reagents in the proportions indicated (per liter).
M1. 0.9% saline 500 0.15 M disodium phosphate 385 0.15 M potassium phosphate 115 The tanned cells are washed several times with saline, and then reconstituted in sterile Alsevers solution.
The preparation of the human red blood cell suspension is carried out under sterile conditions. For this purpose, red blood cells from any blood type can be used. However, Group blood cells are preferably used because of the ready availability of blood donors of this type. Pooled Group 0 blood, collected in acid citrate-dextrose anticoagulant solution, is centrifuged, and the supernatant removed and set aside, and the buffy layer of white blood cells gently removed and discarded. The packed red blood cells are washed several times with Alsevers solution, reconstituted in Alsevers solution, and stored at 2-8 C.
The resuspending medium, used for the final suspension of the human red blood cells, is prepared from defibrinated plasma that is serologically compatible with the suspended human red blood cells, i.e., Group A cells with plasma from Group A, Group B cells with plasma from Group B and Group 0 cells with plasma from Group 0. Defibrinated Group AB plasma (lacking antigens A and B) is compatible with Group A, Group B and Group 0 red blood cells. These plasma supernatants are defibrinated by treatment with bovine thrombin and then diluted 1:3 with Alsevers solution.
As a further stability aid for the fresh blood cells component of the final cell suspension, a metabolic preservative, selected from the class of compounds comprising purines and pyrimidines, is added to the suspending medium at a final concentration of about 34-35 mg. per 100 ml. of cell suspension. A particularly effective preservative agent is adenine (6-arninopurine or a pharmaceutically acceptable acid addition salt, Mann Research Laboratories, Inc., New York, N.Y.).
The following examples are merely illustrative and are not intended to limit the invention, the scope of which is defined by the appended claims.
EXAMPLE I Group 0 blood, collected in aqueous acid citratedextrose anticoagulant, is centrifuged under sterile conditions at 2000 r.p.m. for 20 minutes. The supernatant is gently suctioned off, care being taken not to draw into the supernatant any of the red cells or bufly white layer at the interface of the red cells and supernatant. The supernatant is retained for subsequent dilution with Alsevers solution, and used as a resuspending medium.
The bufly layer (white blood cells) is carefully removed from the top of the packed red blood cells, withdrawing a thin surface of red cells if necessary. The packed red cells are washed twice with Alsevers solution, centrifuged, and stored at 2-8 C. until subsequent mixture With stabilized simulated white blood cells.
EXAMPLE II Fowl red blood cells, preferably turkey cells, are washed 4 times with saline (solution A), (centrifuged for 20 minutes at 3300 r.p.m. after each wash), and after the final wash, are resuspended as an 8% by volume suspension in saline (solution A). To 100 ml. of this 8% suspension is added 100 ml. of a 1% solution by weight of mercuric chloride in saline (solution A) and the resulting suspension is thoroughly mixed. The suspension is incubated at 37 C. for 19 hours, washed 4 times with distilled Water (centrifuging at 1200 r.p.m. for minutes after each wash), and resuspended in saline (solution A) as a 4% 4 by volume suspension. To this 4% suspension is added an equal volume of a 0.0025% weight/volume solution of tannic acid in buffered saline (solution C) and the resulting mixture thoroughly mixed, incubated at 50 C. for 30 minutes, centrifuged, and washed 3 times with distilled water.
EXAMPLE III The supernatant plasma, obtained from Group 0 bloods collected in aqueous acid citrate-dextrose anticoagulant, is diluted with 1:3 with Alsevers solution. The diluted plasma is defibrinated by adding bovine thrombin (Parke- Davis & Co., Detroit, Michigan) at a concentration of 1 unit/ml, and incubated at 37 C. for 1 hour. The clotted material is shaken vigorously to break up the clot, and filtered through a No. 50 Whatman filter pad on a Buchner funnel-suction flask set-up. Adenine sulfate is added at a concentration of 70' mgs./ 100 ml., warming at 37 C. to hasten the dissolution, and the solution filtered successively through 0.45 and 0.22 millipore filter pads.
EXAMPLE IV The method of Example III with plasma from Group AB blood in place of Group 0 plasma.
EXAMPLE V The simulated white blood cells prepared by the method of Example II are reconstituted in sterile A1- severs solution to about 24% hematocrit. This has an approximate count of 750,000-800,000 cells/mmfi. Two m1. of this suspension is further diluted by the addition of 100 ml. of the resuspending medium as prepared by the method of Example III or Example IV.
To a volume of packed human Group 0 blood cells (approximately hematocrit), prepared by the method of Example I, is added an equal volume of the diluted simulated white blood cells suspension referred to above.
The final cell suspension product, containing approximately 34-35 mg./ ml. of adenine, has a red blood cell count of about 4,000,000-5,000,000 cells/mmfi, white blood cell count of 5,000-10,000 cells/mm hemoglobin, 12-16 grams/100 ml., and hematocrit, 43-47%.
Aliquots (2.5 ml.) of the final suspension product, dispensed in glass vials, are stable for approximately 4 weeks when stored at 2-8 C.
What is claimed is:
1. A hematology control fluid comprising a suspension of fresh human red blood cells and tanned fowl red blood cells in a volume of anticoagulant-containing human serologically compatible plasma medium, approximately equal to the packed volume of said human cells at a concentration of about 5,000-l0,000 of said fowl cells per cubic millimeter.
2. The fluid of claim 1 wherein said fresh human red blood cells are Group 0 red blood cells.
3. The fluid of claim 1 wherein said tanned fowl red blood cells are turkey red blood cells.
4. The fluid of claim 1 wherein the anticoagulant in said anticoagulant-containing human plasma medium is acid citrate-dextrose solution.
5. The fluid of claim 1 wherein said plasma medium comprises defibrinated human plasma in aqueous acid citrate-dextrose anticoagulant diluted with Alsevers solution in a volume ratio of about 1:3.
6. The plasma medium of claim 5 wherein said defibrinated human plasma is Group 0 plasma.
7. The plasma medium of claim 5 wherein said defibrinated human plasma is Group AB plasma.
8. The fluid of claim 1 containing about 34-35 mg. per 100 ml. of 6-aminopurine or a pharmaceutically acceptable acid addition salt thereof.
9. The fluid of claim 1 wherein said human red blood cells are present in a concentration of about 4,000,000 to 5,000,000 cells per cubic millimeter, to provide a 6 hemoglobin level of about 12-16 grams per 100 ml. and FOREIGN PATENTS ahanlamri'tof about 43-47% 690,849 7/1964 Canada 252-408 References Cited HAROLD ANSHER, Primary Examiner UNITED STATES PATENTS 5 J. c. GIL, Assistant Examiner 3,293,134 12/1966 Lenahan et a1. 2s2F-408X 3,406,121 10/1968 Jones 252408 US. (:1. X.R. 3,412,037 11/1968 Gochman et a1. 252-408 23-230; 424-3
US802263A 1969-02-25 1969-02-25 Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium Expired - Lifetime US3574137A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80226369A 1969-02-25 1969-02-25

Publications (1)

Publication Number Publication Date
US3574137A true US3574137A (en) 1971-04-06

Family

ID=25183239

Family Applications (1)

Application Number Title Priority Date Filing Date
US802263A Expired - Lifetime US3574137A (en) 1969-02-25 1969-02-25 Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium

Country Status (6)

Country Link
US (1) US3574137A (en)
DE (1) DE2008493C3 (en)
ES (1) ES376863A1 (en)
FR (1) FR2035733A5 (en)
GB (1) GB1215662A (en)
SE (1) SE376485B (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873467A (en) * 1974-02-01 1975-03-25 United Medical Lab Inc Hematologic reference control
US3973913A (en) * 1976-01-29 1976-08-10 Louderback Allan Lee Blood control standard
US3977995A (en) * 1974-10-17 1976-08-31 Baxter Laboratories, Inc. Calibrating fluid for blood cell counting and hemoglobin determination
US4020006A (en) * 1975-08-14 1977-04-26 Icl/Scientific Fluid containing dispersed particles simulating leukocytes and method for producing same
US4062936A (en) * 1974-11-16 1977-12-13 Mochida Seiyaku Kabushiki Kaisha Carrier for immunochemical measurement
US4102810A (en) * 1975-01-13 1978-07-25 Coulter Electronics, Inc. Stabilized hematological reagent solutions
EP0001741A1 (en) * 1977-10-07 1979-05-16 Walter Sarstedt Kunststoff-Spritzgusswerk Means to facilitate blood platelet counting in blood samples
US4160644A (en) * 1977-06-13 1979-07-10 Streck Laboratories, Inc. Platelet reference control and method of preparation
US4179398A (en) * 1977-03-21 1979-12-18 ICN Medical Laboratories, Inc. Platelet control composition
US4198206A (en) * 1977-06-13 1980-04-15 Ryan Wayne L Method for preparing a platelet reference control
DE3017152A1 (en) * 1979-05-07 1980-11-27 Coulter Electronics MEANS FOR THE PRODUCTION OF A BLOOD COMPARATIVE MONITORING, METHOD FOR THEIR PRODUCTION AND DISCHARGING THEREFOR
US4250051A (en) * 1978-12-26 1981-02-10 Coulter Electronics, Inc. Preservative for use in calibrator compositions for blood analysis
US4282326A (en) * 1978-10-12 1981-08-04 Jeanne Moldenhauer Cell culture medium supplement
US4358394A (en) * 1979-05-07 1982-11-09 Coulter Electronics, Inc. Process for preparing whole blood reference controls having long term stability
WO1985005450A1 (en) * 1984-05-18 1985-12-05 Coulter Electronics, Inc. Hematology control compositions for three populations of leukocytes: and methods for their preparation and use in whole blood control systems
US4579824A (en) * 1983-05-18 1986-04-01 Louderback Allan Lee Hematology control
US5039487A (en) * 1987-12-22 1991-08-13 Board Of Regents, The University Of Texas System Methods for quantifying components in liquid samples
US5672474A (en) * 1991-05-09 1997-09-30 Streck Laboratories, Inc. White blood cell hematology control
US5994139A (en) * 1998-04-07 1999-11-30 Coulter International Corp. Stable hematology control composition and method of use
US6200500B1 (en) 1999-08-20 2001-03-13 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6221668B1 (en) 1999-08-20 2001-04-24 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6362003B1 (en) * 1992-02-24 2002-03-26 Coulter Corporation Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof
US6653137B2 (en) 2001-12-03 2003-11-25 Streck Laboratories Inc. Hematology reference control
US6723563B2 (en) 2001-12-03 2004-04-20 Streck Laboratories Inc. Hematology reference control
US20050048657A1 (en) * 1992-02-24 2005-03-03 Young Carole J. Method of using a hematology control product

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816569C1 (en) * 1988-05-14 1989-10-26 Dimitrios Dr. 7500 Karlsruhe De Giannitsis

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873467A (en) * 1974-02-01 1975-03-25 United Medical Lab Inc Hematologic reference control
US3977995A (en) * 1974-10-17 1976-08-31 Baxter Laboratories, Inc. Calibrating fluid for blood cell counting and hemoglobin determination
US4062936A (en) * 1974-11-16 1977-12-13 Mochida Seiyaku Kabushiki Kaisha Carrier for immunochemical measurement
US4102810A (en) * 1975-01-13 1978-07-25 Coulter Electronics, Inc. Stabilized hematological reagent solutions
US4020006A (en) * 1975-08-14 1977-04-26 Icl/Scientific Fluid containing dispersed particles simulating leukocytes and method for producing same
US3973913A (en) * 1976-01-29 1976-08-10 Louderback Allan Lee Blood control standard
US4179398A (en) * 1977-03-21 1979-12-18 ICN Medical Laboratories, Inc. Platelet control composition
US4160644A (en) * 1977-06-13 1979-07-10 Streck Laboratories, Inc. Platelet reference control and method of preparation
US4198206A (en) * 1977-06-13 1980-04-15 Ryan Wayne L Method for preparing a platelet reference control
US4206077A (en) * 1977-10-07 1980-06-03 Djuro Rodjak Agent for facilitating the counting of thrombocytes in blood samples
EP0001741A1 (en) * 1977-10-07 1979-05-16 Walter Sarstedt Kunststoff-Spritzgusswerk Means to facilitate blood platelet counting in blood samples
US4282326A (en) * 1978-10-12 1981-08-04 Jeanne Moldenhauer Cell culture medium supplement
US4250051A (en) * 1978-12-26 1981-02-10 Coulter Electronics, Inc. Preservative for use in calibrator compositions for blood analysis
DE3017152A1 (en) * 1979-05-07 1980-11-27 Coulter Electronics MEANS FOR THE PRODUCTION OF A BLOOD COMPARATIVE MONITORING, METHOD FOR THEIR PRODUCTION AND DISCHARGING THEREFOR
US4299726A (en) * 1979-05-07 1981-11-10 Coulter Electronics, Inc. Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor
US4358394A (en) * 1979-05-07 1982-11-09 Coulter Electronics, Inc. Process for preparing whole blood reference controls having long term stability
US4579824A (en) * 1983-05-18 1986-04-01 Louderback Allan Lee Hematology control
US4704364A (en) * 1984-05-18 1987-11-03 Coulter Electronics, Inc. Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems
WO1985005450A1 (en) * 1984-05-18 1985-12-05 Coulter Electronics, Inc. Hematology control compositions for three populations of leukocytes: and methods for their preparation and use in whole blood control systems
US5380664A (en) * 1984-05-18 1995-01-10 Coulter Corporation Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems
US5039487A (en) * 1987-12-22 1991-08-13 Board Of Regents, The University Of Texas System Methods for quantifying components in liquid samples
US5672474A (en) * 1991-05-09 1997-09-30 Streck Laboratories, Inc. White blood cell hematology control
US5677145A (en) * 1991-05-09 1997-10-14 Streck Laboratories, Inc. White blood cell hematology control
US5731205A (en) * 1991-05-09 1998-03-24 Streck Laboratories, Inc. White blood cell hematology control
US5981282A (en) * 1991-05-09 1999-11-09 Streck Laboratories, Inc. White blood cell hematology control
US6362003B1 (en) * 1992-02-24 2002-03-26 Coulter Corporation Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof
US20050048657A1 (en) * 1992-02-24 2005-03-03 Young Carole J. Method of using a hematology control product
US20050221497A1 (en) * 1992-02-24 2005-10-06 Carole Young Quality control method
US20050221496A1 (en) * 1992-02-24 2005-10-06 Young Carole J Quality control method
US20050095719A1 (en) * 1992-02-24 2005-05-05 Young Carole J. Quality control method
US20050048656A1 (en) * 1992-02-24 2005-03-03 Young Carole J. Quality control method
US5994139A (en) * 1998-04-07 1999-11-30 Coulter International Corp. Stable hematology control composition and method of use
US6399388B1 (en) 1999-08-20 2002-06-04 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6406915B2 (en) 1999-08-20 2002-06-18 Streck Laboratoreis, Inc. Hematology control and system for multi-parameter hematology measurements
US6403377B1 (en) 1999-08-20 2002-06-11 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6200500B1 (en) 1999-08-20 2001-03-13 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6221668B1 (en) 1999-08-20 2001-04-24 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6723563B2 (en) 2001-12-03 2004-04-20 Streck Laboratories Inc. Hematology reference control
US6653137B2 (en) 2001-12-03 2003-11-25 Streck Laboratories Inc. Hematology reference control

Also Published As

Publication number Publication date
ES376863A1 (en) 1972-05-01
SE376485B (en) 1975-05-26
FR2035733A5 (en) 1970-12-18
DE2008493B2 (en) 1979-01-25
DE2008493C3 (en) 1979-09-27
GB1215662A (en) 1970-12-16
DE2008493A1 (en) 1970-09-03

Similar Documents

Publication Publication Date Title
US3574137A (en) Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium
US3640896A (en) Process for stabilizing fowl red blood cells
Ballas et al. Red cell membrane and cation deficiency in Rh null syndrome
EP1212613B1 (en) Hematology control and system for multi-parameter hematology measurements
Spaet et al. Mechanism of platelet plug formation and role of adenosine diphosphate
JP4673871B2 (en) Red blood cell suspension medium
US4045176A (en) Preparation of optically clear serum
Lux et al. Diminished spectrin extraction from ATP-depleted human erythrocytes. Evidence relating spectrin to changes in erythrocyte shape and deformability.
Lewis et al. A one-stage method for the determination of accelerator globulin.
Zuzel et al. A method for measuring plasma ristocetin cofactor activity—normal distribution and stability during storage
Eber et al. Hereditary stomatocytosis: consistent association with an integral membrane protein deficiency
US5426031A (en) Extraction methods for preparing thromboplastin reagents
US5504193A (en) Extraction methods for preparing thromboplastin reagents
EP0154522A2 (en) Method for sphering and fixing whole blood erythrocytes
CN112305232A (en) Mixed quality control substance of blood and specific protein and quality control method thereof
US4403042A (en) Detection of cell membrane antigens and corresponding antibodies
Ross et al. Paroxysmal nocturnal hemoglobinuria presenting as aplastic anemia in a child: Case report with evidence of deficient leukocyte acetylcholinesterase activity
US6368785B1 (en) Anti-coagulation of blood, plasma or synovial fluid products using iso-citrate
Litosch et al. Sickle red cell calcium metabolism: Studies on Ca2+‐Mg2+ ATPase and ca‐binding properties of sickle red cell membranes
US6759246B1 (en) Hematology control composition including lymphocyte analogs and method for preparation and use
Birgegård Serum ferritin: physiological and methodological studies
Greener et al. In vitro studies on methyl mercury distribution in human blood
EP0186476A2 (en) Diagnostic kit and method for assaying blood components
Hackett et al. THE CLOTTING OF THE BLOOD OF AN AMPHIBIAN, BUFO MARINUS LINN: 1. PROTHROMBIN‐THROMBIN AND “FIBRINOGEN‐FIBRIN” STAGES
Jung et al. The electrophoretic mobility heterogeneity of human platelet subpopulations of different buoyant densities

Legal Events

Date Code Title Description
AS Assignment

Owner name: WARNER-LAMBERT COMPANY, 201 TABOR RD., MORRIS PLAI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:PFIZER INC.;REEL/FRAME:003853/0905

Effective date: 19810409